EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Germline pathogenic variants in succinate dehydrogenase genes: implications from a single-institution study

Sanjana S Awasty, Carly Fisher, Pamela L Brock, Lawrence S Kirschner

Endocrine Oncology · 2026-01-01 · 6 (1)

DOI: 10.1530/eo-25-0113 ↗
AbstractBibliografische Angaben

Abstract

Abstract Context Germline pathogenic variants (PVs) in the succinate dehydrogenase (SDHx) genes are associated with inherited pheochromocytoma and paraganglioma (PPGL). Because of the high incidence of germline PVs, genetic testing is recommended for all cases of PPGL; relatives may, thus, be found through cascade testing. PPGL-associated genes are also included on cancer genetics panels, which may lead to variant identification related to other tumors. After PV detection, screening recommendations entail biochemical/radiologic testing and frequent surveillance. Objective The aim of this study was to assess the consequences and impact of these approaches in a cohort of individuals with germline PVs in the SDHx genes. Design Natural history study. Setting A single academic medical center. Patients or other participants A total of 156 patients with SDHx PVs were identified and included over a period of 10 years. Interventions None. Main outcome measures We report the distribution of PVs, rationale for genetic screening, tumor incidence, and second genetic variants. Results Of 156 patients with variants in the SDHx genes, PVs in SDHB were the most common. In probands tested for non-PPGL tumors, SDHA PVs were the most common, whereas SDHD cases were never detected in this manner. We also identified individuals with variants in a second cancer-associated gene. For individuals not found to have a tumor at initial presentation, the rate of tumor development was <5%. Conclusion SDHx PVs may be more common than expected, and there are gene-specific patterns of ascertainment. Future research is needed to evaluate the role of modifier variants on tumor risk. Reconsideration of surveillance guidelines may be appropriate given the low frequency of new lesions in tumor-free carriers.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →